493 related articles for article (PubMed ID: 22058260)
1. Dermatomyositis and polymyositis: new treatment targets on the horizon.
Hak AE; de Paepe B; de Bleecker JL; Tak PP; de Visser M
Neth J Med; 2011 Oct; 69(10):410-21. PubMed ID: 22058260
[TBL] [Abstract][Full Text] [Related]
2. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.
Dastmalchi M; Grundtman C; Alexanderson H; Mavragani CP; Einarsdottir H; Helmers SB; Elvin K; Crow MK; Nennesmo I; Lundberg IE
Ann Rheum Dis; 2008 Dec; 67(12):1670-7. PubMed ID: 18272672
[TBL] [Abstract][Full Text] [Related]
3. [Dermatomyositis and polymyositis: clinical aspects and treatment].
Hachulla E
Ann Med Interne (Paris); 2001 Nov; 152(7):455-64. PubMed ID: 11965087
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory Myopathies with Cutaneous Involvement: from Diagnosis to Therapy.
Dourmishev LA
Folia Med (Plovdiv); 2017 Mar; 59(1):7-13. PubMed ID: 28384112
[TBL] [Abstract][Full Text] [Related]
5. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients.
Marie I; Menard JF; Hatron PY; Hachulla E; Mouthon L; Tiev K; Ducrotte P; Cherin P
Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1748-55. PubMed ID: 20722047
[TBL] [Abstract][Full Text] [Related]
6. Polymyositis: is there anything left? A retrospective diagnostic review from a tertiary myositis centre.
Loarce-Martos J; Lilleker JB; Parker M; McHugh N; Chinoy H
Rheumatology (Oxford); 2021 Jul; 60(7):3398-3403. PubMed ID: 33367878
[TBL] [Abstract][Full Text] [Related]
7. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy.
Ichimura Y; Matsushita T; Hamaguchi Y; Kaji K; Hasegawa M; Tanino Y; Inokoshi Y; Kawai K; Kanekura T; Habuchi M; Igarashi A; Sogame R; Hashimoto T; Koga T; Nishino A; Ishiguro N; Sugimoto N; Aoki R; Ando N; Abe T; Kanda T; Kuwana M; Takehara K; Fujimoto M
Ann Rheum Dis; 2012 May; 71(5):710-3. PubMed ID: 22258483
[TBL] [Abstract][Full Text] [Related]
8. Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis.
Mammen AL
Ann N Y Acad Sci; 2010 Jan; 1184():134-53. PubMed ID: 20146695
[TBL] [Abstract][Full Text] [Related]
9. Current diagnosis and treatment of polymyositis and dermatomyositis.
Sasaki H; Kohsaka H
Mod Rheumatol; 2018 Nov; 28(6):913-921. PubMed ID: 29669460
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory myopathies in Nigerians: case series and literature review.
Adelowo OO; Edomwonyi U; Olaosebikan H
Afr J Med Med Sci; 2013 Jun; 42(2):143-9. PubMed ID: 24377199
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory myopathies: evaluation and management.
Greenberg SA
Semin Neurol; 2008 Apr; 28(2):241-9. PubMed ID: 18351525
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic strategies in idiopatic inflammatory myopathies].
Chakour R; Leimgruber A; Bart PA; Spertini F
Rev Med Suisse; 2009 Apr; 5(199):812-8. PubMed ID: 19441746
[TBL] [Abstract][Full Text] [Related]
13. Role of cytokines and chemokines in idiopathic inflammatory myopathies.
De Paepe B; Creus KK; De Bleecker JL
Curr Opin Rheumatol; 2009 Nov; 21(6):610-6. PubMed ID: 19726994
[TBL] [Abstract][Full Text] [Related]
14. Features of polymyositis and dermatomyositis in the elderly: a case-control study.
Pautas E; Chérin P; Piette JC; Pelletier S; Wechsler B; Cabane J; Herson S
Clin Exp Rheumatol; 2000; 18(2):241-4. PubMed ID: 10812498
[TBL] [Abstract][Full Text] [Related]
15. Effects of immunosuppressive treatment on interleukin-15 and interleukin-15 receptor α expression in muscle tissue of patients with polymyositis or dermatomyositis.
Zong M; Loell I; Lindroos E; Nader GA; Alexanderson H; Hallengren CS; Borg K; Arnardottir S; McInnes IB; Lundberg IE
Ann Rheum Dis; 2012 Jun; 71(6):1055-63. PubMed ID: 22267334
[TBL] [Abstract][Full Text] [Related]
16. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients.
Efthimiou P; Schwartzman S; Kagen LJ
Ann Rheum Dis; 2006 Sep; 65(9):1233-6. PubMed ID: 16476710
[TBL] [Abstract][Full Text] [Related]
17. Decreased expression of interleukin-1alpha, interleukin-1beta, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis.
Lundberg I; Kratz AK; Alexanderson H; Patarroyo M
Arthritis Rheum; 2000 Feb; 43(2):336-48. PubMed ID: 10693873
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic advances in myositis.
Aggarwal R; Oddis CV
Curr Opin Rheumatol; 2012 Nov; 24(6):635-41. PubMed ID: 22955021
[TBL] [Abstract][Full Text] [Related]
19. Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy.
Venalis P; Lundberg IE
Rheumatology (Oxford); 2014 Mar; 53(3):397-405. PubMed ID: 23970542
[TBL] [Abstract][Full Text] [Related]
20. Alpha-chemokine receptors CXCR1-3 and their ligands in idiopathic inflammatory myopathies.
De Paepe B; De Keyzer K; Martin JJ; De Bleecker JL
Acta Neuropathol; 2005 Jun; 109(6):576-82. PubMed ID: 15937690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
